Sanger Sequencing
A Global Strategic Business Report
MCP34316
WHAT'S BEHIND OUR DATA?
140857226
DOMAIN TRANSCRIPTS6080276
BRANDS TRACKED1729341
FEATURED COMPANIES22574
TOPICS COVERED82719
MARKET SEGMENTS91
KEY INDUSTRIES1574
CURATION TEAM4761909
DECISION MAKERSEXECUTIVE ENGAGEMENTS BY TIER (55)
3
CXO5
VICE PRESIDENT10
DIRECTOR25
MANAGER12
MARKETING
REQUEST FULL-STACK INDEX
Includes 350+ pages validated sources
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Sanger Sequencing Market to Reach US$8.9 Billion by 2030
The global market for Sanger Sequencing estimated at US$3.4 Billion in the year 2024, is expected to reach US$8.9 Billion by 2030, growing at a CAGR of 17.5% over the analysis period 2024-2030. Shotgun Sequencing, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Targeted Gene Sequencing segment is estimated at 19.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$894.2 Million While China is Forecast to Grow at 16.6% CAGR
The Sanger Sequencing market in the U.S. is estimated at US$894.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.9% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.
Global "Sanger Sequencing" Market – Key Trends & Drivers Summarized
Why Does Sanger Sequencing Remain Relevant in a Genomics-Driven World?
Despite the rise of next-generation sequencing (NGS) platforms, Sanger sequencing retains its relevance due to its unparalleled accuracy, simplicity, and cost-effectiveness for specific applications. It remains the gold standard for sequence validation, single-gene diagnostics, and small-scale research projects. This method is highly valued in clinical genomics for confirming variants identified through high-throughput methods. Researchers favor Sanger sequencing for its ability to deliver long, high-fidelity reads, often up to 1000 base pairs, which are ideal for detecting insertions, deletions, or mutations in targeted regions. Diagnostic labs use it extensively for genetic testing in rare diseases and hereditary conditions. Sanger’s minimal data output also simplifies storage and analysis, especially in resource-limited settings. It offers the added advantage of faster turnaround times when compared to complex NGS workflows. As the genomics market diversifies into veterinary, agricultural, and microbiological fields, Sanger sequencing’s robustness makes it an essential complementary technology. Its adaptability to capillary electrophoresis systems and integration with existing lab infrastructure continues to support its application across both legacy and emerging use cases.
How Is Technology Enhancing the Precision and Accessibility of Sanger Sequencing?
Recent advancements are significantly refining the Sanger sequencing workflow, reducing costs and improving throughput. Automation in DNA extraction, PCR cleanup, and reaction preparation has minimized manual errors and increased sample handling efficiency. Improvements in dye-terminator chemistry and capillary electrophoresis systems have enhanced signal clarity, speed, and data resolution. Compact, benchtop sequencers now allow decentralized sequencing in smaller labs and clinics. Integration with cloud-based bioinformatics platforms has also made data analysis, interpretation, and reporting more accessible to non-specialists. AI tools are being used to detect low-frequency variants with greater confidence. Reagent miniaturization is helping reduce per-sample costs, and open-source labware is facilitating low-cost adoption in educational institutions. Barcode tagging of samples is enabling higher levels of multiplexing, increasing lab productivity. Furthermore, real-time monitoring tools are ensuring quality control at every stage. As a result, Sanger sequencing is no longer just a manual lab procedure; it is evolving into a semi-automated, intelligent platform that fits neatly into the broader genomics ecosystem.
In Which Fields Is the Demand for Sanger Sequencing Growing Most Rapidly?
Sanger sequencing is experiencing renewed demand in specific verticals where accuracy and confirmation are paramount. In clinical diagnostics, it`s frequently used for confirmatory testing of germline mutations, especially in cancer predisposition and rare disease panels. Its role is expanding in pharmacogenomics, where precise genotyping is essential for tailored therapies. Agricultural genomics is another growing field, with Sanger used for crop genotyping, trait confirmation, and breeding programs. In microbiology, it is employed for pathogen identification, antibiotic resistance analysis, and plasmid verification. Veterinary medicine is increasingly adopting Sanger for genetic screening in pedigree animals and disease tracking. Forensic labs continue to use the method for mitochondrial DNA analysis due to its high-quality read output. Educational institutions also rely on Sanger systems for training students in sequencing fundamentals due to their reliability and ease of use. The rise in outsourcing of sequencing services to contract research organizations (CROs) is further supporting steady market demand. These sector-specific requirements highlight Sanger’s unique role as a foundational technology in modern genomics.
The Growth In The Sanger Sequencing Market Is Driven By Several Factors...
The expansion of the Sanger sequencing market is underpinned by a blend of enduring technological appeal and shifting industry needs. Demand for high-confidence confirmatory testing in clinical diagnostics is sustaining its usage, especially as companion diagnostics gain traction in precision medicine. The increasing number of research initiatives in academic and government institutions is also fueling market expansion. Cost-effectiveness and ease of setup are making Sanger the method of choice for low-throughput labs, especially in developing regions. The growing complexity of NGS datasets has led to increased reliance on Sanger sequencing for final validation. Regulatory agencies prefer Sanger data for approvals due to its proven reproducibility and accuracy. Continued investments in lab automation and benchtop sequencing devices are making the technology more scalable. Moreover, the market is benefiting from growing collaborations between hospitals, CROs, and molecular diagnostic companies. With applications ranging from infectious disease surveillance to plant breeding, Sanger sequencing is thriving as a complementary solution in the broader genomic toolkit.
SCOPE OF STUDY
The report analyzes the Sanger Sequencing market by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Shotgun Sequencing, Targeted Gene Sequencing, Other Types); Application (Diagnostics, Personalized Medicine, Forensics, Other Applications); End-Use (Government Research Institutes, Diagnostic Labs, Pharma & Biotech Companies, Other End-Uses).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..
SELECT PLAYERS
AAT Bioquest; Azenta Life Sciences (GENEWIZ); BaseClear; BGI Genomics; Eurofins Genomics; GenScript; Illumina; LGC Biosearch Technologies; Macrogen; MCLAB; Microsynth AG; Nucleics; Psomagen; QIAGEN; Roche Applied Science; SeqLab; Source BioScience; Synlab; Thermo Fisher Scientific; Zymo Research
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy |
| World Market Trajectories |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| Sanger Sequencing – Global Key Competitors Percentage Market Share in 2025 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2025 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Continued Use in Targeted DNA Sequencing Applications Sustains Demand for Sanger Sequencing |
| Clinical Diagnostics and Genetic Validation Workflows Strengthen Business Case for Precision Sequencing |
| Pharma and Biotech R&D Activities Throw the Spotlight on Sangers Reliability in Mutation Detection |
| Growing Preference for Low-Throughput, High-Accuracy Techniques in Niche Applications Drives Adoption |
| Cost-Effectiveness in Academic and Clinical Labs Sustains Long-Term Relevance of Sanger Platforms |
| Rising Prevalence of Genetic Disorders Accelerates Use in Confirmatory Testing |
| Expansion of Outsourced Sequencing Services Creates New Demand from Research Institutions |
| Next-Generation Sequencing Limitations in Long Homopolymer Regions Create Opportunities for Sanger |
| Regulatory Compliance in Clinical Genomics Favors Established and Validated Technologies |
| Integration with NGS Workflows for Hybrid Pipelines Expands Market Potential |
| Low Entry Cost and Training Requirements Sustain Adoption in Emerging Markets and Universities |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Sanger Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030 |
| World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Shotgun Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Shotgun Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Targeted Gene Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Targeted Gene Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Diagnostic Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Diagnostic Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Forensics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Forensics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| USA 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Canada 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| JAPAN |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Japan 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| CHINA |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| China 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| EUROPE |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR |
| Europe 6-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| FRANCE |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| France 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| GERMANY |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Germany 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Italy 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| UNITED KINGDOM |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| UK 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of Europe 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| ASIA-PACIFIC |
| Sanger Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Type - Shotgun Sequencing, Targeted Gene Sequencing and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of World 6-Year Perspective for Sanger Sequencing by Type - Percentage Breakdown of Value Sales for Shotgun Sequencing, Targeted Gene Sequencing and Other Types for the Years 2025 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by End-Use - Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of World 6-Year Perspective for Sanger Sequencing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Other End-Uses, Government Research Institutes and Diagnostic Labs for the Years 2025 & 2030 |
| Rest of World Recent Past, Current & Future Analysis for Sanger Sequencing by Application - Diagnostics, Personalized Medicine, Forensics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR |
| Rest of World 6-Year Perspective for Sanger Sequencing by Application - Percentage Breakdown of Value Sales for Diagnostics, Personalized Medicine, Forensics and Other Applications for the Years 2025 & 2030 |
COMPETITIVE METRICS
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]